Clinical Trials
23 trialsNCT04895735 2026-06-04
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04325828 2026-05-08
YATAGARASU
Janssen Pharmaceutical K.K.
Phase 2 Active not recruiting
NCT05074940 2026-05-08
Amivantamab in Adenoid Cystic Carcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT00939627 2026-03-10
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
Phase 2 Completed
NCT03172624 2025-12-18
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03146650 2024-01-18
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
Northwestern University
Phase 2 Unknown
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT01175980 2020-08-03
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01044433 2020-03-19
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT00524017 2020-03-12
Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01604772 2019-05-01
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02123511 2019-04-30
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
Mayo Clinic
Phase 2 Completed
NCT01613768 2018-09-28
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
University of Washington
Phase 2 Completed
NCT00509665 2018-07-12
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
Medical University of South Carolina
Phase 2 Completed
NCT00859937 2018-04-20
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00509002 2017-11-24
Iressa Study in Patients With Salivary Gland Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00503776 2017-06-20
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00095563 2017-04-18
Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
National Cancer Institute (NCI)
Phase 2 Completed
NCT01256385 2017-03-27
MAESTRO HN
National Cancer Institute (NCI)
Phase 2 Completed
NCT00095628 2017-03-06
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00507767 2014-10-01
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00492089 2014-05-09
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00639769 2012-09-14
Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Completed